Let's break down Indoco Remedies Limited (INDOCO) — from its financial performance to how the market is valuing the stock.
Indoco Remedies Revenue Trend
Revenue fell 8.4% year-over-year to ₹1,665 Cr in FY2025 for Indoco Remedies Limited.
On a 10-year view, revenue grew at 6.9% per year from ₹857 Cr to ₹1,665 Cr. Respectable, though not in the high-growth bracket.
In terms of scale, Indoco Remedies Limited's ₹1,665 Cr in annual revenue positions it as a mid-sized pharmaceuticals company.
| Year | Revenue | YoY % |
|---|---|---|
| FY2025 | ₹1,665 Cr | -8.4% |
| FY2024 | ₹1,817 Cr | +8.9% |
| FY2023 | ₹1,669 Cr | +8.3% |
| FY2022 | ₹1,541 Cr | +24.1% |
| FY2021 | ₹1,242 Cr | — |
View Indoco Remedies Limited's full 10-year revenue trend with CAGR analysis →
Indoco Remedies Profitability
After earning ₹97.0 Cr in FY2024, Indoco Remedies Limited swung to a loss of ₹78.0 Cr in FY2025.
FY2025 diluted EPS of ₹-8.45 was down from the ₹10.51 reported in FY2024.
Is Indoco Remedies Undervalued
Indoco Remedies Limited shares are currently trading at ₹221.76.
Craytheon calculates intrinsic value using the P/E Ratio and EPS Growth models. Both appear in the Valuation Models cards below.
Valuation Models
Indoco Remedies Shareholding Pattern
At 58.9%, the promoter stake has been flat for the past 4 quarters.
FII ownership stands at 1.3%, up from the 1.2% recorded a year ago.
DII holding is at 17.7%, down from 18.2% in the year-ago quarter.
| Quarter | Promoter | FII | DII | Public |
|---|---|---|---|---|
| Jun 2026 | 58.9% | 1.3% | 17.7% | 22.0% |
| Mar 2026 | 58.9% | 0.9% | 18.1% | 21.9% |
| Dec 2025 | 58.9% | 1.1% | 18.1% | 21.8% |
| Sep 2025 | 58.9% | 1.2% | 18.2% | 21.6% |
Track quarterly shareholding changes for Indoco Remedies Limited →
Indoco Remedies Balance Sheet
Proportional view as of 3 Aug 2026. Hover blocks for details.
Assets
Liabilities & Equity
In FY2025, the total asset base came in at ₹24.30B, up 13.3% YoY from ₹21.45B.
Property, Plant & Equipment accounts for 45.7% of the total, ahead of Inventories (17.3%) and Receivables (14.5%).
Capital structure: 41.9% equity, 40.9% debt, 17.2% operating liabilities. Over the year, debt is up 47.9% and equity is down 8.3%.
Balance sheet composition — FY 2025
| Category | Value |
|---|---|
| Cash & ST Investments | 120.96M |
| Receivables | 3.52B |
| Inventories | 4.19B |
| Property, Plant & Equipment | 11.10B |
| Investments | 14.63M |
| Intangibles & Goodwill | 1.92B |
| Other Assets | 3.42B |
| Category | Value |
|---|---|
| Equity | 10.18B |
| Short-term Debt | 4.51B |
| Long-term Debt | 5.43B |
| Trade Payables | 2.08B |
| Other Liabilities | 2.10B |
What Stands Out About Indoco Remedies
To sum up Indoco Remedies Limited's financial position: the data paints a clear picture for investors evaluating this pharmaceuticals stock.
Revenue of ₹1,665 Cr in FY2025, down 8.4% year-over-year.
Long-term revenue has been compounding at 6.9% annually over 10 years.
The company reported a net loss of ₹78.0 Cr in FY2025.
Unlock Full Analysis
For the complete 10-year financial history with interactive charts and growth analysis, explore Indoco Remedies Limited's detailed profile on Craytheon.